Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon Nov 16, 2021 5:59pm

152 Views

Post# 34134023

3.89 - Extremely Undervalued in Comparison to peers

The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our peer

Current Market cap 189 mil US

We are waiting on Phase II Human Clinical Trial Data by a third party for a 20 billion a year unmet market.

BLU is currently 695 mil market cap for Chronic Cough (Phase 2)

VXRT is currently 888 mil market cap US Oral Vaccines

SAVA is 2 billion US market cap for Blood Cancer (Phase 2)

CYDY is 1.1 billion US market cap for Antibodies

TRIL was 2.2 billion buyout (Phase 2)

As we wait on data, there is no reason why we are not at a 695 million market cap of $11.20. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season